These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26334204)

  • 21. At the crossroads of cancer stem cells and targeted therapy resistance.
    Wang A; Qu L; Wang L
    Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining targeted drugs to stop resistant tumors.
    Kaiser J
    Science; 2011 Mar; 331(6024):1542-5. PubMed ID: 21436437
    [No Abstract]   [Full Text] [Related]  

  • 23. Promising strategy developed to target drug-resistant cancer cells.
    Thorne J
    Future Med Chem; 2014 Apr; 6(6):603. PubMed ID: 25028759
    [No Abstract]   [Full Text] [Related]  

  • 24. Molecularly targeted therapies: mechanisms of resistance. Abstracts of the AACR (American Association for Cancer Research) Special Conference. May 9-12, 2012. San Diego, California, USA.
    Clin Cancer Res; 2012 May; 18(10 Suppl):A1-68, B1-68, IA1-15, PR1-8. PubMed ID: 23534065
    [No Abstract]   [Full Text] [Related]  

  • 25. New hopes in the fight against cancer: a special issue on targeted anti-cancer drug discovery and cell signaling.
    Cheng X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):1-2. PubMed ID: 26578705
    [No Abstract]   [Full Text] [Related]  

  • 26. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
    Cruzalegui F
    Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
    [No Abstract]   [Full Text] [Related]  

  • 27. The roadmap of TRAIL apoptotic pathway-targeted cancer therapies: What is next?
    Bellail AC; Hao C
    Expert Rev Anticancer Ther; 2012 May; 12(5):547-9. PubMed ID: 22594889
    [No Abstract]   [Full Text] [Related]  

  • 28. Attacking cancer with molecularly targeted agents.
    Santoro M; Carlomagno F
    Curr Opin Pharmacol; 2013 Aug; 13(4):483-5. PubMed ID: 23871444
    [No Abstract]   [Full Text] [Related]  

  • 29. Challenges in the Discovery of Novel Therapeutic Agents in Cancer.
    Nagaraju GP; Kamal MA
    Curr Drug Metab; 2019; 20(13):1004-1005. PubMed ID: 32072882
    [No Abstract]   [Full Text] [Related]  

  • 30. Mapping the Pathways of Resistance to Targeted Therapies.
    Wood KC
    Cancer Res; 2015 Oct; 75(20):4247-51. PubMed ID: 26392071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heat-Shock Protein 90-Targeted Nano Anticancer Therapy.
    Rochani AK; Ravindran Girija A; Borah A; Maekawa T; Sakthi Kumar D
    J Pharm Sci; 2016 Apr; 105(4):1454-66. PubMed ID: 26886301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerating safe drug development: an ideal approach to approval.
    Grever MR
    Hematology Am Soc Hematol Educ Program; 2013; 2013():24-9. PubMed ID: 24319158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
    Oxnard GR
    Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AACR meeting highlights new findings on drug resistance, targeted therapies.
    Printz C
    Cancer; 2013 Sep; 119(18):3259. PubMed ID: 24037707
    [No Abstract]   [Full Text] [Related]  

  • 35. New research on the treatment of small HER2-positive breast cancers.
    Krop IE
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):124-7. PubMed ID: 24892258
    [No Abstract]   [Full Text] [Related]  

  • 36. New skin cancer target could delay drug resistance.
    Oncology (Williston Park); 2013 Mar; 27(3):164. PubMed ID: 23687783
    [No Abstract]   [Full Text] [Related]  

  • 37. Using high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.
    Wajnberg G; Passetti F
    Expert Opin Drug Discov; 2016; 11(3):257-68. PubMed ID: 26787005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sphingosine kinase 1 as an anticancer therapeutic target.
    Gao Y; Gao F; Chen K; Tian ML; Zhao DL
    Drug Des Devel Ther; 2015; 9():3239-45. PubMed ID: 26150697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Novel Mechanisms of Resistance to Investigational Molecularly Targeted Drugs].
    Noguchi K
    Yakugaku Zasshi; 2017; 137(2):151-160. PubMed ID: 28154324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.